Technology
Amydis detects molecular biomarkers in the eye
Accessible, affordable, adoptable, designed to fit the clinical workflow
Amydis patent-protected eye tracer formulated to address different markets.
Use imaging technologies and workflows already established in eye care practices.
Molecular biomarker images captured during office visit to power AI-based insights.
Why the eye?
The eye reveals pathologies that lead to vision loss and offers valuable insights into overall health. The eye provides a non-invasive view of cells connected to the brain, making it a window into neurodegeneration. Eye vasculature provides insights into other vascular organ systems such as the heart. Molecular biomarkers in the eye allow for detection of diseases in the earliest stages possible.
- There will be an increase in demand of eye care providers because of aging and use of digital screens.
- Myopia (near sightedness) is increasing in kids due to use of digital screens; affects 2.6B people.
- Presbyopia (far sightedness) impacts all adults, typical onset in early 40s; affects 1.8B people.
- Baby Boomers/aging population on Medicare are required to have annual eye exam.
- Eye care providers are readily accessible; 90% of the Medicare population lives within 25 minutes of an ophthalmologist and 14 minutes of an optometrist.
Therefore, eye care providers are positioned to become earliest point of healthcare, including becoming healthcare hubs for detecting neurodegenerative and cardiological diseases through the eye.
Why Amydis?
Amydis is a leader in developing ocular tracers to enable breakthrough disease detection and insights.
- Amydis’ first-in-class ocular tracers unlock the opportunity for robust in-vivo labeling of disease-related molecular biomarkers in the eye during routine eye examinations.
- The Amydis tracers are novel small molecule fluorophores that bind selectively to amyloid and amyloid-like deposits of disease-related biomarkers, including those formed by Aβ and α-synuclein.
- Amydis tracers generate a robust signal that can be detected by diagnostic cameras that are routinely used by eye care providers today.
- The addition of ocular molecular biomarker data creates an unprecedented opportunity for breakthrough insights in differential diagnosis, prediction, and prognosis of ophthalmic, neurodegenerative, and cardiological diseases.
- Through extensive scientific rigor and support from the NIH and Michael J Fox Foundation, Amydis has proven that these tracers can accurately detect, label, and quantify molecular biomarkers.
- The Company is currently in human clinical trials.
Why now?
Digital health technology is advancing at an unprecedented speed.
- Non-invasive eye diagnostic imaging devices with the ability to capture high-resolution three-dimensional data in clinical settings are becoming standard of care.
- These devices capture data in seconds to allow clinicians to evaluate structural and vascular biomarkers in the retina related to ophthalmic, neurodegenerative, and cardiological health.
- Molecular biomarkers in the eye are invaluable for the early detection and monitoring of overall health.
- The ability to visualize and analyze molecular biomarkers in the eye accurately, reliably, and precisely is currently not possible in clinical settings.
- Amydis’ ocular molecular biomarker data has the potential to transform healthcare by empowering eye care providers with unprecedented insights to effectively participate in detecting and monitoring early signs of several treatable neurodegenerative and cardiological diseases.
The eye contains molecular biomarkers linked to multiple diseases of the body.
Eye
The molecular biomarker, amyloid beta (A ), has been shown to be present in the retina of patients with two neurodegenerative diseases that lead to blindness: glaucoma and age-related macular degeneration.
Heart
The molecular biomarker, transthyretin (TTR), typically detected in systemic organs such as the heart, kidney, and liver, has been shown to be present in the front of the eye of patients with TTR systemic amyloidosis.
Brain
The molecular biomarkers, amyloid beta and alpha synuclein typically detected in the brain, have been shown to present in the retina of patients with Alzheimer’s disease and Parkinson’s disease.
